Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Vytora Health vs Wisp

Vytora Health
Graded #79

Lower grade

vs+2.700000000000003
Wisp
Graded #59

Higher grade

The verdict

Wisp takes it — 75/100 to 72.3/100.

Wisp grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWisp +24
59
83
Dose & formulationWisp +3
85
88
Clinical oversightVytora Health +14
96
82
Labs & monitoringVytora Health +2
55
53
FulfillmentVytora Health +30
96
66
Contract termsWisp +35
20
55
Vytora Health · left barWisp · right bar

The numbers

MetricVytora HealthWisp
WeighScore72.3/10075/100
GradeCC
Scorecard rank#79#59
Semaglutide$180/mo (all doses, compounded)$225/mo (compounded oral)
Tirzepatide$249/mo (all doses, compounded)$99/mo (starting dose, brand-name)
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
Vytora Health

Graded #79 · C

Strengths

  • All 50 states plus DC, with per-state video-vs-audio compliance disclosed
  • Both compounded and brand-name options on one platform — uncommon
  • LegitScript Approved and HIPAA compliant
  • Pharmacy partners named publicly: Vials Pharmacy (TX) and Greenwich Biosciences
  • Operating entity disclosed: Wasef Health, PC (Pinellas Park, FL)

Where it loses points

  • Brand-name Mounjaro/Zepbound at $1,399/mo is near retail — insured patients may do better via LillyDirect Self Pay ($449-$699/mo)
  • Compounded tirzepatide at $249/mo is mid-market, above the $149-199 floor
  • Dose tiers aren't broken out — 'all doses included' means low-dose patients pay the same as high-dose
  • Initial consultation cost not shown on the public pricing page
  • Limited per-prescriber state licensure detail
Wisp

Graded #59 · C

Strengths

  • Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
  • LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
  • Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary

Where it loses points

  • Sublingual compounded semaglutide hasn't been tested in humans, per Wisp's own page — only the injectables have FDA efficacy data
  • Pharmacy partners not named
  • States served not listed publicly

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard